Head-to-head evidence
BAT1706 vs bevacizumab-awwb
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
BAT1706 · Avzivi
Marketed by Bio-Thera Solutions
NCT03329911 · Phase 3 · completed
The trial was randomized, double-blind, and actively controlled, with 651 participants, and used a clinical tumor-response endpoint assessed by RECIST 1.1. However, the week-18 primary endpoint comparison is unclear because only response counts are posted and no statistical analysis is reported.
bevacizumab-awwb · MVASI
Marketed by Amgen
NCT01966003 · Phase 3 · completed
This randomized, quadruple-blind, active-controlled Phase 3 trial in 642 patients with advanced non-small cell lung cancer compared the biosimilar bevacizumab-awwb with reference bevacizumab, both added to chemotherapy. Objective response rates were closely matched (39.0% vs 41.7%), and the prespecified statistical test showed the two products were clinically equivalent.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1706's landscape · bevacizumab-awwb's landscape